Iloperidone for the treatment of schizophrenia: An updated clinical review

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 1, 2012, Pages 34-44

  Weiden, Peter J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antipsychotic; Extrapyramidal side effects; Iloperidone; Psychopharmacology

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; PAROXETINE; RISPERIDONE; VENLAFAXINE; ZIPRASIDONE;

AKATHISIA; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; MAINTENANCE THERAPY; ORTHOSTATIC HYPOTENSION; OUTPATIENT CARE; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; HOSPITALIZATION; HUMANS; ISOXAZOLES; PIPERIDINES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84859715500     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.6.1.5     Document Type: Review

References (27)

1. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11(1):59-67.
2. Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today (Barc) 2010;46(8):567-579.
3. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956(2):349-357. (Pubitemid 35351402)
4. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68(1):29-39.
5. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317(2-3):417-423. (Pubitemid 27014051)
6. Kalkman HO, Feuerbach D, Lotscher E, Schoefft er P. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Life Sci 2003;73(9):1151-1159. (Pubitemid 36724916)
7. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996;124(1-2):87-94. (Pubitemid 26111437)
8. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2010;64(6):707-718.
9. Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol 2010;6(12):1551-1564.
10. Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010;4:33-48.
11. Baroldi P, Wolfgang CD, Fisher D. A pharmacokinetic (PK)-pharmacodynamic (PD) relationship exists for efficacy of iloperidone, a novel investigational atypical antipsychotic agent. Paper presented at: American Psychiatric Association Annual Meeting; May 19-24, 2007; San Diego, CA.
12. Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res 2011;131(1-3):75-81.
13. Stahl SM, Baroldi P, Feeney J, Wolfgang CD. The metabolic profile of iloperidone: summary of phase II and III schizophrenia trials. Presented at the 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC.
14. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, et al. Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl) 2008;199(1):15-27.
15. Loh C, Leckband SG, Meyer JM, Turner E. Risperidone-induced retrograde ejaculation: case report and review of the literature. Int Clin Psychopharmacol 2004;19(2):111-112. (Pubitemid 38316770)
16. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol 2010;30(1):68-71.
17. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011;168(2):193-201.
18. Weiden P, Cutler AJ, Polymeropoulos M, Wolfgang C. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-19. (Pubitemid 351397672)
19. Weiden PJ. Switching antipsychotic medications: not enough, too often, or just right? Am J Psychiatry 2011;168(9):882-884.
20. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry 2007;68 Suppl 6:14-23. (Pubitemid 47026642)
21. Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty JP; Roadmap Survey. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. J Clin Psychiatry 2007;68 Suppl 7:1-48. (Pubitemid 47122210)
22. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1145-1158. (Pubitemid 37464959)
23. Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, et al. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry 2011 July 12. [Epub ahead of print]
24. Potkin SG. New advances in the treatment of schizophrenia. Introduction. J Clin Psychopharmacol 2008;28(2 Suppl 1):S1-3.
25. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11.
26. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35. (Pubitemid 351397674)
27. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-28. (Pubitemid 351397673)